ASH 2020 | Inotuzumab ozogamicin for treating pediatric R/R ALL
Erica Brivio, MD, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands, discusses the results of the Phase II ITCC-059 study (NTR5736) investigating single-agent inotuzumab ozogamicin (InO) for treating pediatric CD22-positive relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Following the findings of tolerability and early anti-leukemic activity in the Phase I study portion, the established recommended Phase II dose was used to assess the overall response rate to InO. The study found that InO was well tolerated and achieved an ORR of 81.5%, with 95% of responders reaching measurable residual disease-negativity. Further trials assessing InO in combination with chemotherapy are ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Erasmus MC received institutional funding for the ITCC059 trial from Pfizer Inc.
